Mundipharma announces results of pivotal phase III study for flutiform in paediatric asthma

The data shows the efficacy and tolerability of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, over 12 weeks in children with asthma aged 5 to <12. Read more

10 Sep 2014 10:49